Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Yes on Issue 2 Campaign Rolls out TV Ad Featuring Ohio EpiPen Moms on EpiPen’s Skyrocketing Price Hike—from $100 to More Than $600

Ohio Taxpayers for Lower Drug Prices
Posted on: 12 Sep 17

The Yes on Issue 2 campaign has launched a new statewide TV ad featuring two Ohio mothers that rely on EpiPens to combat their children's life-threatening allergic reactions. The ad explains that EpiPens contain less than $1 of epinephrine, but the cost for the medicine has skyrocketed from $100 to more than $600 while the drug manufacturer's CEO makes $97 million annually.

View ad here:

“We’ve made a big commitment with this ad because we know that the outrageous price of vital medications affects every single Ohioan. While these big drug company CEOs get paid millions of dollars each year and use their billion dollar companies to fund distorted TV ads against us, regular Ohioans are paying the price at the pharmacy. They can’t afford it anymore, and voting Yes on Issue 2 will lower drug prices for millions of Ohioans and save taxpayers $400 million,” said Dennis Willard, spokesperson for Yes on Issue 2.

FDA Accuses Mylan Over Failed EpiPens

The Food and Drug Administration (FDA) has accused Pfizer Inc. of inadequately investigating “hundreds of complaints” that EpiPens “failed to operate during life-threatening emergencies, including some situations in which patients subsequently died.” The FDA did not make more details public. Pfizer manufactures EpiPens, which treat allergic reactions, for the drugmaker Mylan.

At issue is the EpiPen mechanism designed to inject a proper dose of epinephrine into a person suffering from an allergy-triggered shock. Mylan outraged parents and lawmakers in the past year when it set the EpiPen list price at $600, a huge price runup for a generic drug therapy. In August, Mylan also announced it has agreed to pay $465 million to settle a lawsuit alleging it overcharged the federal government for its EpiPens.

Source: New York Times.

Background on Ohio Ballot Issue 2

The Yes on Issue 2 campaign is a broad-based, bi-partisan coalition. More than 200,000 Ohio voters signed petitions to put an amendment on the ballot in November that will lower drug prices for over 4 million Ohioans, including 164,000 children, save taxpayers $400 million annually, reduce healthcare costs for everyone and teach greedy drug companies and their CEOs a lesson.

You can learn more by visiting yesonissue2.com or following us on Facebook and Twitter.

Paid for by Ohio Taxpayers for Lower Drug Prices

View source version on businesswire.com: http://www.businesswire.com/news/home/20170911006324/en/

Business Wire
www.businesswire.com

Last updated on: 12/09/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.